Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

Othera Pharmaceuticals48 enrolled

Overview

The purpose of this study is to evaluate the safety and potential efficacy of a new drug, OT-730 ophthalmic solution (eye drops), in reducing intraocular pressure in the eyes of patients with open angle glaucoma or ocular hypertension. It will be compared with commercial timolol and placebo eye drops.

Glaucoma is a group of diseases of the eye that can result in irreversible vision loss due to damage to the optic nerve. Elevated intraocular pressure (IOP) is one factor associated with glaucoma. Currently-available medication used to lower IOP includes beta-blocking agents, which can have undesirable side effects on the cardiac and respiratory systems. The OT-730 ophthalmic solution contains OT-730, a prodrug that, when applied as an eyedrop, metabolizes to OT-705, an active beta blocker. The OT-730 ophthalmic solution is being studied to see how well it lowers IOP in patients with a diagnosis of open angle glaucoma or ocular hypertension. It will be compared with a well known beta blocker, timolol maleate ophthalmic solution, and with a placebo eye drop, in order to assess its ability to lower IOP without the typical side effects of other beta blockers.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Glaucoma, Open-Angle Ocular Hypertension

Interventions

OT-730 ophthalmic solutionDRUG

one eye drop twice daily

timolol maleate ophthalmic solutionDRUG

one eye drop twice daily

OT-730 placeboDRUG

one eye drop twice daily

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * healthy subjects, 18 to 80 years of age, any gender * diagnosis of primary open angle, pseudoexfoliative or pigmentary glaucoma or ocular hypertension Exclusion Criteria: * have VA worse than 20/200, * cataract that compromises visualization of fundus, * history of lack of response to ocular beta blocker therapy, * uncontrolled intraocular pressure, * angle closure glaucoma or occludable angles, * retinal detachment, macular hole, progressive vision loss, any progressive retinal disease or neurologic disease other than glaucoma that is likely to worsen visual field or acuity during the course of the study, * a history of, or any current condition contraindicated with use of a beta blocker (e.g., chronic obstructive pulmonary disease, bronchial asthma, congestive heart failure, myasthenia gravis, hypoglycemia, bradycardia, etc), * chronic use of steroids, * any disease that, in the opinion of the investigator, may put the patient at significant risk, * taking systemic beta blockers

Locations (5)

Unnamed facility

Artesia, California, United States

Unnamed facility

Roswell, Georgia, United States

Unnamed facility

Charlotte, North Carolina, United States

Unnamed facility

High Point, North Carolina, United States

Unnamed facility

Outcomes

Primary Outcomes

Assess the safety profile of OT-730

Time frame: 8 days

Change from baseline in intraocular pressure

Time frame: Day 6

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.